{"Title": "Alzheimer's disease: Where next for anti-amyloid therapies?", "Year": 2017, "Source": "Brain", "Volume": "140", "Issue": 4, "Art.No": null, "PageStart": 853, "PageEnd": 855, "CitedBy": 30, "DOI": "10.1093/brain/awx059", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85028552628&origin=inward", "Abstract": null, "AuthorKeywords": null, "IndexKeywords": ["Alzheimer Disease", "Amyloid", "Amyloid beta-Peptides", "Amyloidogenic Proteins", "Amyloidosis", "Humans", "Immunotherapy"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85028552628", "SubjectAreas": [["Neurology (clinical)", "MEDI", "2728"]], "AuthorData": {"56210513900": {"Name": "Hardy J.", "AuthorID": "56210513900", "AffiliationID": "60019953", "AffiliationName": "UCL Institute of Neurology, Dementia Research Institute"}, "7006241978": {"Name": "De Strooper B.", "AuthorID": "7006241978", "AffiliationID": "60019953", "AffiliationName": "UCL Institute of Neurology, Dementia Research Institute"}}}